13 December 2018
Expensya
Expensya reinvents expense reporting thanks to innovative features and to the latest technology trends. From receipts to accounting, their web and mobile solution automates...
All
13 December 2018
Israeli microbiome co BiomX teams with Johnson & Johnson
Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...
13 December 2018
Expensya raises 4M€ in Series A Financing co-lead by ISAI and Seventure Partners
The company, that develops and sells an innovative expense reports software, aims at spurring its international development.
5 November 2018
Next decade set to herald industry confidence in microbiome-based therapies, says new report
Taking on board learnings from challenges already faced and focusing on advanced, longer-term studies of variables within microbiome research will be key to fostering...
26 October 2018
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies
25 October 2018
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund
The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to...
23 October 2018
Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease
Enterome, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered...
16 October 2018
LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
4 October 2018
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...